Talk:Alemtuzumab

This is the talk page for discussing improvements to the Alemtuzumab article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Alemtuzumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

vandalism

I think this article is vandalised once. It has no gangsters, and the diff is shown here: [1] --BlakeCS 23:32, 24 February 2007 (UTC)[reply]

Sarcoid

doi:10.1111/j.1365-2141.2007.06687.x - can cause sarcoid! JFW | T@lk 22:44, 23 June 2007 (UTC)[reply]

new study on MS

http://news.bbc.co.uk/2/hi/health/7680641.stm —Preceding unsigned comment added by 78.24.121.60 (talk) 06:09, 23 October 2008 (UTC)[reply]

Have used this to replace dead yahoo URL. - Rod57 (talk) 09:41, 25 October 2011 (UTC)[reply]

Campath being trialed for MS treatment

Campath is currently being trialed by cambridge university to treat MS. —Preceding unsigned comment added by 60.241.168.49 (talk) 05:07, 27 May 2009 (UTC)[reply]

Campath / license change controversy

This is mentioned twice, we really need to remove one. Any preference which should go? (I'd say the second mention, so the relicense is under the controversy). Unless anyone has any strong feeling either way I'll update Jtowler (talk) 07:21, 20 March 2013 (UTC)[reply]

Current (Sept 2014) availability outside US?

per a, shall we politely say, obsessive website [a]:

"Take the case of Sanofi's Lemtrada, a drug to treat multiple sclerosis that has been approved all over the world. Taken once a year, it alleviates the symptoms of the disease and delays the onset of paralysis. Although the drug has already been approved to treat leukemia-so it is safe-FDA did not approve the design of its Phase III study and refused to approve it last December. Sanofi resubmitted the drug with additional data in May, but no word yet from the FDA."

[a] http://www.realclearmarkets.com/articles/2014/09/23/the_fda_should_be_in_ebola-mode_all_the_time_101288.html

- The Wikipedia article says the drug's been withdrawn from sale pending relabeling and re-targetting (at higher prices). Anyone know whether it's still available and in which countries? Thanks wiki-ny-2007 (talk) 15:22, 27 September 2014 (UTC)[reply]

What change of dose and price from CLL to MS

What dose and price applied to CLL ? What value of sales for CLL ? What dose and price is now applied to MS ? - Rod57 (talk) 12:18, 17 October 2016 (UTC)[reply]

UK price for Lemtrada alemtuzumab 10 mg/mL, net price 1.2-mL vial = £7045.00[2] ~ £56,000 (for 5 + 3 infusions)[3]- Rod57 (talk) 12:29, 17 October 2016 (UTC)[reply]

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Alemtuzumab. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

Added archive https://web.archive.org/web/20110714063804/http://www.campath.com/hcp/AboutCampath.html to http://www.campath.com/hcp/AboutCampath.html

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 14:37, 30 June 2017 (UTC)[reply]

Querying status as a secondary treatment for MS - it is now very often first-line, and urgently recommended

article says "In MS it is generally only recommended if other treatments have not worked"

This was the case until a fiveish years ago, but there is a growing consensus that it should be first-line, because the earlier it and other 'highly effective-class' drugs are taken the greater the long-term benefits are.

The consensus doesn't seem to have been firmly established but might be an idea to add a clause to say

"In MS it is generally only recommended if other treatments have not worked, though numerous clinicians are arguing it should becomee a first-line therapy"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501364/ 2A01:4B00:9D30:C000:D5F3:ED30:1712:1887 (talk) 08:50, 24 August 2023 (UTC)[reply]